# Phase I (PH I) Mad Refractory Solid Tumor Study

> **NCT00099606** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 60 (—)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00099606
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 60 (—)
- **Last updated:** 2011-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099606, "Phase I (PH I) Mad Refractory Solid Tumor Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00099606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*